BlackRock’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,081,587
| Closed | -$116M | – | 5648 |
|
|
2021
Q1 | $116M | Buy |
3,081,587
+122,556
| +4% | +$3.06M | ﹤0.01% | 2108 |
|
|
2020
Q4 | $50.3M | Buy |
2,959,031
+839,885
| +40% | +$10.5M | ﹤0.01% | 2467 |
|
|
2020
Q3 | $9.96M | Sell |
2,119,146
-61,229
| -3% | -$311K | ﹤0.01% | 3220 |
|
|
2020
Q2 | $13.3M | Sell |
2,180,375
-360,852
| -14% | -$1.49M | ﹤0.01% | 3018 |
|
|
2020
Q1 | $5.77M | Buy |
2,541,227
+5,408
| +0.2% | +$23K | ﹤0.01% | 3294 |
|
|
2019
Q4 | $11.6M | Sell |
2,535,819
-420,484
| -14% | -$1.67M | ﹤0.01% | 3167 |
|
|
2019
Q3 | $11.5M | Buy |
2,956,303
+73,715
| +3% | +$404K | ﹤0.01% | 3141 |
|
|
2019
Q2 | $17.4M | Buy |
2,882,588
+63,634
| +2% | +$608K | ﹤0.01% | 2924 |
|
|
2019
Q1 | $37.8M | Sell |
2,818,954
-220,961
| -7% | -$2.52M | ﹤0.01% | 2420 |
|
|
2018
Q4 | $28.3M | Buy |
3,039,915
+127,777
| +4% | +$1.52M | ﹤0.01% | 2544 |
|
|
2018
Q3 | $40.5M | Buy |
2,912,138
+48,618
| +2% | +$723K | ﹤0.01% | 2493 |
|
|
2018
Q2 | $45.3M | Buy |
2,863,520
+210,031
| +8% | +$3.67M | ﹤0.01% | 2414 |
|
|
2018
Q1 | $45.6M | Buy |
2,653,489
+457,380
| +21% | +$8.92M | ﹤0.01% | 2317 |
|
|
2017
Q4 | $48.1M | Sell |
2,196,109
-43,408
| -2% | -$1.4M | ﹤0.01% | 2315 |
|
|
2017
Q3 | $91.6M | Buy |
2,239,517
+27,339
| +1% | +$858K | ﹤0.01% | 1900 |
|
|
2017
Q2 | $66.6M | Buy |
2,212,178
+17,889
| +0.8% | +$558K | ﹤0.01% | 2059 |
|
|
2017
Q1 | $79.3M | Buy |
2,194,289
+2,187,986
| +34,713% | +$96.4M | ﹤0.01% | 1923 |
|
|
2016
Q4 | $316K | Sell |
6,303
-6,128
| -49% | -$322K | ﹤0.01% | 1891 |
|
|
2016
Q3 | $653K | Sell |
12,431
-337
| -3% | -$16.1K | ﹤0.01% | 1649 |
|
|
2016
Q2 | $528K | Buy |
12,768
+10,842
| +563% | +$472K | ﹤0.01% | 1648 |
|
|
2016
Q1 | $79K | Buy |
1,926
+1,044
| +118% | +$35.9K | ﹤0.01% | 2114 |
|
|
2015
Q4 | $36K | Buy |
882
+456
| +107% | +$15.3K | ﹤0.01% | 2246 |
|
|
2015
Q3 | $7K | Hold |
426
| – | – | ﹤0.01% | 2908 |
|
|
2015
Q2 | $11K | Hold |
426
| – | – | ﹤0.01% | 2749 |
|
|
2015
Q1 | $10K | Hold |
426
| – | – | ﹤0.01% | 2750 |
|
|
2014
Q4 | $12K | Hold |
426
| – | – | ﹤0.01% | 2675 |
|
|
2014
Q3 | $5K | Hold |
426
| – | – | ﹤0.01% | 3091 |
|
|
2014
Q2 | $7K | Buy |
+426
| New | +$6.11K | ﹤0.01% | 3028 |
|
BlackRock's FPRX Position: Q2 2021 in Review
BlackRock sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 3,081,587 shares — an estimated $116M sold.
BlackRock first reported a position in FPRX in Q2 2014 and held it in 28 quarters. The position peaked at $116M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- BlackRock reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- BlackRock sold 3,081,587 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $116M.
- BlackRock first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 28 quarters.
- BlackRock's Five Prime Therapeutics, Inc. position peaked at $116M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on BlackRock's 13F filing for Q2 2021, filed 11 Aug 2021.